Thermo Fisher Scientific Inc. (NYSE:TMO) is Mendel Money Management’s 6th Largest Position

Mendel Money Management lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,782 shares of the medical research company’s stock after selling 128 shares during the period. Thermo Fisher Scientific comprises approximately 2.5% of Mendel Money Management’s investment portfolio, making the stock its 6th biggest holding. Mendel Money Management’s holdings in Thermo Fisher Scientific were worth $5,609,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Legacy Investment Solutions LLC bought a new stake in shares of Thermo Fisher Scientific in the third quarter valued at about $26,000. Barrett & Company Inc. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $28,000. FPC Investment Advisory Inc. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $28,000. Missouri Trust & Investment Co bought a new position in Thermo Fisher Scientific in the fourth quarter worth approximately $29,000. Finally, Pillar Financial Advisors LLC purchased a new stake in Thermo Fisher Scientific during the fourth quarter worth $29,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on TMO. Morgan Stanley upped their price objective on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. Scotiabank lifted their price objective on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a “sector perform” rating in a research report on Monday, February 3rd. Royal Bank of Canada set a $693.00 target price on shares of Thermo Fisher Scientific in a research report on Friday, January 31st. Wells Fargo & Company upped their price target on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. Finally, Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price on the stock in a research note on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $653.23.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $513.77 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The firm’s 50 day simple moving average is $544.56 and its 200-day simple moving average is $554.22. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88. The stock has a market capitalization of $193.83 billion, a price-to-earnings ratio of 31.08, a PEG ratio of 2.99 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.33%. The ex-dividend date is Friday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s payout ratio is presently 10.41%.

Insiders Place Their Bets

In related news, SVP Michael A. Boxer sold 3,775 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares of the company’s stock, valued at approximately $5,759,736.32. This trade represents a 25.87 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the transaction, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at $9,582,009.17. The trade was a 1.80 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 23,900 shares of company stock worth $13,106,062. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.